GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genovate Biotechnology Co Ltd (ROCO:4130) » Definitions » Net Issuance of Debt

Genovate Biotechnology Co (ROCO:4130) Net Issuance of Debt : NT$0.0 Mil (TTM As of Mar. 2025)


View and export this data going back to 2012. Start your Free Trial

What is Genovate Biotechnology Co Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Genovate Biotechnology Co's net issuance of debt for the three months ended in Mar. 2025 was NT$0.0 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Mar. 2025 was NT$0.0 Mil.

Genovate Biotechnology Co Net Issuance of Debt Historical Data

The historical data trend for Genovate Biotechnology Co's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genovate Biotechnology Co Net Issuance of Debt Chart

Genovate Biotechnology Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Genovate Biotechnology Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Genovate Biotechnology Co Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genovate Biotechnology Co Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Genovate Biotechnology Co's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Genovate Biotechnology Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genovate Biotechnology Co Ltd (ROCO:4130) » Definitions » Net Issuance of Debt
Comparable Companies
TPE:1762 ROCO:6676 ROCO:1295 ROCO:6748 ROCO:6704 ROCO:6461 ROCO:7754 ROCO:6846 ROCO:6892 ROCO:4168 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
No.1, First Industrial Road, Hsin-Chu Expanded Park, Hukou Township, Guangdong Province, Hsin-Chu county, Hsin-Chu, TWN, 303036
Website
http://www.genovate-bio.com
Genovate Biotechnology Co Ltd develops, produces, manufactures, and markets pharmaceutical preparations, drug substances, and intermediates. The company is also engaged in sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases, etc.

Genovate Biotechnology Co Headlines

No Headlines